ArticleSAGE open medical case reports2026
Rare and varied presentations of plasmablastic lymphoma: A case series.
Article in SAGE open medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmablastic lymphoma is a rare and aggressive variant of diffuse large B-cell lymphoma characterized by heterogeneous clinical presentations and poor outcomes. This study presents a comprehensive review integrated with three cases demonstrating diverse clinical manifestations and treatment outcomes. We conducted a detailed analysis of three plasmablastic lymphoma cases diagnosed and treated at our institution between 2022 and 2023, incorporating clinical presentations, diagnostic findings, treatment approaches, and outcomes. These cases were analyzed in the context of current literature and treatment guidelines. The cases included an HIV-positive male with perianal plasmablastic lymphoma, an HIV-negative female with gastric plasmablastic lymphoma arising from marginal zone lymphoma, and an HIV-negative female with retroperitoneal plasmablastic lymphoma. Two patients achieved complete remission with bortezomib plus dose-adjusted-etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin therapy, while one experienced treatment failure and death. Epstein-Barr virus positivity was observed in two cases. Treatment-related complications included peripheral neuropathy and organ failure. The cases demonstrated variable outcomes independent of HIV status but correlating with age and performance status. Our series highlights the diverse presentation patterns of plasmablastic lymphoma and validates known prognostic factors while demonstrating the efficacy of contemporary treatment approaches. The outcomes underscore the importance of individualized therapy and careful patient selection for intensive treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.